A 67-Year-Old-Man with Metastatic Prostate Cancer - Episode 4
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.